EIC Accelerator for university spin-offs: academic partners, subcontracting and IP

I am a Verified Expert Evaluator and a venture builder. I have reviewed more than 3,700 companies and proposals, and a good share of the deep-tech ones came out of a university lab. The questions are always similar, so this piece answers them in order. I rely on two official documents, the EIC Accelerator Guide for Applicants v6.0 and the EIC Work Programme 2026. Where a point comes from them I say so; where it is my own judgment as an evaluator, I say that too.

One applicant, no consortium: where does the university fit?

The EIC Accelerator funds one company. The documents list who can apply: a single start-up or SME (the Guide says explicitly "including spin-outs") established in an EU Member State or a Horizon Europe Associated Country; a small mid-cap, but only for the investment component or, exceptionally, blended finance; or one or more natural persons or legal entities who intend to set up an SME (the company must exist before the grant agreement is signed) or to invest in one. The grant agreement is signed with the beneficiary company only.

I found no mechanism in either document for a second beneficiary, an associated partner or a co-applicant. So the university is not a partner in the Horizon Europe consortium sense. A university or a hospital is not on the list of eligible applicants either, unless it acts through a company that qualifies.

Two details help spin-offs in particular. Natural persons can apply before the company exists, and they need their own Participant Identification Code to start the submission. And if you are a natural person, the short proposal video can include future team members, or explain how you will assemble the team. The company, however, has to be established by the time the grant agreement is signed.

The academic partner as subcontractor (and the other options)

"Is it better for the academic partner to be a beneficiary or a subcontractor?" In the Accelerator that choice does not exist. Beneficiary is not available, so the real options are: paid subcontractor, or unpaid supporter.

What the documents say about subcontracting

• The grant component covers innovation activities (TRL 6 to 8) and reimburses up to 70% of eligible costs, as a lump sum, up to EUR 2.5 million. The company funds the other 30% from its own resources.
• The Work Programme says the grant component "may be used for subcontracting", and adds that this includes, only if justified, activities essential to the objectives of the project. So subcontracting is allowed, and you are expected to justify it.
• You propose the lump sum with a detailed budget table. Subcontracting is one of its cost categories. The costs in that table must meet the normal EU eligibility conditions, and purchases and subcontracting in particular must ensure best value for money and be free from conflicts of interest. If the table contains ineligible costs, the grant can be reduced, even after the project has started or ended.
• The 25% flat rate for indirect costs is calculated excluding subcontracting costs.
• Entities established in China, Russia, Belarus or in non-government-controlled areas of Ukraine, and entities under EU restrictive measures, cannot take part in any capacity, subcontractors included. Check this if your academic partner is outside the EU.

What is not specified. I found no percentage cap on subcontracting in the Guide or in the Work Programme, and the Guide does not discuss subcontracting at all. Do not assume that no cap exists: read the budget table instructions and the call document on the Funding and Tenders Portal before you fix your numbers.

How I would structure it (my judgment)

• Bound the scope. Subcontract defined tasks with deliverables and a price: characterisation, testing, a validation study, access to a facility. Do not subcontract the core development. A panel reads the company's own capability, and a spin-off that outsources its main work looks like a shell.
• Budget only TRL 6 to 8 work. The lab work that got you to TRL 5 is the entry ticket, not an eligible cost. If the lab contract mostly continues research, expect questions.
• Watch the conflict of interest. If the professor holds shares or a role in the spin-off and runs the lab you are paying, the contract needs arm's-length terms and a visible price logic. This is my reading of the "free from conflicts of interest" condition.
• Put the results in writing. The subcontract should say who owns what is produced and what the company can do with it. I verified no specific Horizon Europe rule on results generated by subcontractors, so settle it contractually.

Other ways to involve the university

A letter of intent from the university or a hospital is one of the supporting documents the full proposal can include. Beyond that, an advisory agreement with the professor, a paid access agreement to equipment, or research funded by a separate national project all work, as long as the proposal shows what the company controls. They do not need a budget line, but they need to be real and written down.

Intellectual property: licence, assignment and what evaluators check

IP is part of the Excellence criterion. The question evaluators answer is whether the innovation has adequate IP protection and a sound IP strategy to enter the market. At full proposal stage you upload an IP strategy annex, including a freedom to operate (FTO) analysis if available. The Work Programme adds that the Agency may object, under conditions set in the grant agreement, to a transfer of ownership or the licensing of results.

Neither document tells you to hold the IP by assignment or by licence. That choice is yours. What follows is what I look for as an evaluator.

• A clean chain of title. Who invented it, under which employment contract, which institutions co-own it. Several universities or a hospital as co-owners slow everything down.
• Control, not just access. Assignment gives the cleanest answer. A licence can work if it is exclusive in your field, long enough to cover the project and the exit, with the right to sublicense and to enforce, and without a clause that lets the university take it back if the company is sold or raises money.
• Signed, not "under negotiation". A licence that is still being negotiated at full proposal stage is a weak point, because the Step 3 jury is made up of entrepreneurs and investors who will ask the question.
• Freedom to operate. A patent filing shows ownership of your own claim. FTO shows you will not infringe someone else's. They answer different questions.

Red flags I see

• The core patent is still in the university's name with no signed agreement.
• A non-exclusive licence on the main technology.
• Termination or reversion on change of control.
• Background IP that stays in the lab and is needed to run the product.
• A royalty or equity stake for the university that an investor would not accept, which matters because the Accelerator often leads to an equity investment.

The team: professor as advisor or CEO

The Implementation criterion asks whether the company has the skills to develop the innovation and scale the company, whether governance is adequate, whether the team is sufficiently incentivised, and whether skill gaps have a credible plan to fill them. The short proposal asks for information on the CEO, or the highest managing position, and the video features up to three core team members. The full proposal includes CVs of key personnel and a cap table.

The jury of entrepreneurs, investors and ecosystem experts reads this the way an investor would. My experience with spin-offs, as opinion and not rule:

• Who runs the company every day? A brilliant scientist who stays a full-time academic and lists an "interim CEO" or a hire "to be recruited" raises the first doubt. A professor as scientific founder or advisor, with a named commercial CEO, is a story juries understand.
• Skin in the game. The cap table shows who is incentivised. A team that holds almost nothing, with most of the value sitting at the university, is hard to defend.
• Dependence on the lab. If equipment, know-how and the people who run the experiments are all in the lab, show the plan: which capabilities move into the company, which stay outsourced, and by when.
• A gap with a plan is acceptable. The Guide asks for a credible plan to fill gaps, not a perfect team on day one.

When the Accelerator is not the right route

The Accelerator expects the innovation to have completed all aspects of TRL 5 and funds the work from TRL 6. If your spin-off is earlier than that, or if the university needs to be a funded partner, other EIC instruments fit better.

• EIC Transition. Open to single applicants (SMEs, spin-offs, start-ups, research organisations, universities) or small consortia of 2 to 5 entities. Grants up to EUR 2.5 million to validate and demonstrate technology, starting at TRL 3 or 4 and aiming at TRL 5 or 6. The proposal must build on results of an eligible earlier EU-funded project; the Work Programme lists the eligible ones.
• EIC Pathfinder. For earlier, high-risk research. Pathfinder Open accepts only consortia of at least three independent legal entities in different countries, and universities are named as examples of eligible partners. Pathfinder Challenges also accepts single applicants or consortia of at least two.
• Your national route for the stages before TRL 5. Check the call documents for current deadlines, which change every year.

Choosing between them is the same logic as in my guide on EIC Accelerator vs Horizon Europe: match the instrument to your TRL and to who must be funded. If you have the Accelerator in mind, the complete application guide covers the process, and how evaluators score a proposal shows what the panel does with the team and IP sections. You can also read what winning companies in your technology proposed in the winners database.

Questions